Marco's Morning Report

Wednesday, July 29, 2026 · Cape Coral, FL
Normal day · full briefing

Morning, Marco. The food-safety story got bigger overnight in a way that's actually operational for you: the FDA's own outbreak page now lists twelve ongoing foodborne outbreaks at once, and eight of them have no identified source. Meanwhile the Iran pause ended after three days, and the Mets put up a 14-run night on their way out of contention. Coffee, then sleep.

A · Top Stories

Update

It isn't one lettuce outbreak — the FDA is now tracking twelve simultaneous foodborne outbreaks, eight with no known source

Bruce Y. Lee, MD, MBA wrote up the FDA's Investigations of Foodborne Illness Outbreaks table yesterday in Forbes: twelve entries currently carry an "ongoing" status — four Cyclospora, three Salmonella, two E. coli, two Listeria monocytogenes, and one Clostridium botulinum in a powdered infant formula — and for eight of the twelve the product is still listed as "Not Yet Identified." On July 22 the FDA added a brand-new Cyclospora outbreak (ref #1392, 72 cases, source unknown, traceback initiated), one day after HHS Secretary Robert F. Kennedy Jr. said on July 21 that "we do have the outbreak under control." The cyclosporiasis footprint is now 41 states, clustered in nine (IL, IN, KS, KY, MI, OH, OK, PA, WV); Michigan alone is past 9,200 cases and at least 160 hospitalizations, Ohio past 2,500. (Those are state-reported cyclosporiasis counts across all four investigations; the single Taylor Farms–linked multistate outbreak that CDC tracks separately stands at 1,947 laboratory-confirmed cases and 98 hospitalizations.) The three Salmonella lines: Javiana (listed July 22, 106 cases, source unknown), Oranienburg (July 8, 81 cases, source unknown), and Enteritidis (June 10, 96 cases) — the last tied to a Midwest Poultry Services shell-egg recall covering sell-by/best-by dates July 20–Aug. 17 under Country Morning, Cal-Maine Sunups, Brookshire's, Simple Truth, and Kroger labels.

Why it matters to you: the practical shift is that "recent produce exposure" is no longer a single-question screen. A frail 80-year-old coming in dehydrated after three weeks of watery diarrhea could plausibly belong to any of four different Cyclospora investigations, and eight of the twelve have no product to ask about — so exposure history won't rule anything in or out. That pushes the work onto the diagnostic: routine stool culture and O&P will miss Cyclospora unless you specifically request modified acid-fast staining or a multiplex GI PCR panel that includes it. The C. botulinum powdered-infant-formula entry is the one to keep in the back of your mind if a floppy-infant call ever comes your way from the ED.

Talking point / action: worth a two-minute item at your next group meeting — confirm which GI PCR panel your lab runs and whether Cyclospora is on it, and whether a sulfa alternative is pre-decided for TMP-SMX-allergic patients. Both are the kind of thing you don't want to be figuring out at 4 a.m. in August.

Update

The three-day Iran pause ended yesterday — Iran says there were never any talks

Tuesday's relative calm broke when U.S. Central Command said it intercepted a "surprise attack" by Iran on U.S. forces in the region; hours later CENTCOM announced joint U.S.–Saudi strikes against Iran-aligned groups in Iraq (CNN live coverage, July 28). President Trump had characterized the pause as Iran's request — "they asked us very nicely, 'please stop, let's meet'" — but Iranian Foreign Ministry spokesman Esmaeil Baghaei stated flatly that no negotiations with the U.S. are underway and that Tehran "will never allow the United States to determine the timing of war and peace" (Al Jazeera). What talks did happen during the lull were Iran–Oman, about the Strait of Hormuz — not U.S.–Iran.

Why it matters to you: mostly through the supply chain rather than the news cycle. Crude had settled back toward the low $80s on the assumption the pause was the front edge of a ceasefire; that assumption is now weaker. The downstream items that actually reach your unit — IV fluids, injectables, sterile packaging, and freight cost on everything else — move on the same logistics that Hormuz and the Red Sea do, and you're heading into hurricane season with Gulf refining capacity already the seasonal variable.

Talking point / action: nothing to do today. If your pharmacy starts flagging allocation on common injectables in the next few weeks, this is the upstream reason, and it's worth knowing before you're told a substitution is "just a formulary thing."

The Senate is holding a hearing today on AI-generated fraud aimed at older adults

The Senate Special Committee on Aging convenes this morning for a hearing titled "The AI Deception Machine: Deepfakes, Chatbots, and the New Frontier of Senior Fraud" (Holland & Knight Health Dose, July 28). Separately today, the Senate Homeland Security and Governmental Affairs Committee takes testimony from Dr. Anthony Fauci, and tomorrow the HELP Committee marks up the Health Information Privacy Reform Act (S. 3097) along with the nomination of Sean Kaufman as HHS Assistant Secretary for Preparedness and Response.

Why it matters to you: financial exploitation of elderly patients is a clinical problem that shows up disguised as something else — the patient who can't afford the medication they were discharged on last month, the family member who suddenly controls the phone, the "confusion" that's actually shame. Voice-cloned grandchild-in-trouble calls have made this materially harder to detect than it was two years ago, because the classic tell (the story doesn't sound like them) is gone. It also intersects with capacity assessment: an older adult who has been successfully deceived by a convincing synthetic voice has not thereby demonstrated impaired decision-making capacity, and it's worth being explicit about that distinction when family members bring it up as evidence.

Talking point / action: ask case management whether your discharge workflow has any elder financial-exploitation screen at all. Most hospitalist services don't, and it costs one question.

B · The Debate

Should the FDA's food traceability rule be in force now instead of 2028?

Why it's live right now: FSMA Rule 204 — which would require companies to keep lot-level records for high-risk foods and hand them to regulators within 24 hours — was supposed to take effect in January 2026. The FDA pushed compliance out 30 months to July 20, 2028, and the FY2026 agriculture appropriations act then barred the agency from spending any money enforcing it before that date. A Cyclospora outbreak that began in May has since reached 41 states, and most of the FDA's currently open investigations still have no identified product. Traceback is exactly what the rule was built to accelerate.

For — the rule should be in force

Thomas Gremillion, Director of Food Policy, Consumer Federation of America (Bloomberg Government); Bill Marler, Food Safety News

The case rests on arithmetic rather than principle: the rule was meant to be law in January, the outbreak started in May, and investigators are still trying to identify products in July. "It's hard for me to believe that if that rule had not gone forward as scheduled with the compliance date now in effect, that it wouldn't have sped up this investigation," Gremillion said. Lot-level records with a 24-hour turnaround are the difference between naming a grower in days and reconstructing a supply chain from paper invoices over months — and every week of that gap is more product moving and more people exposed. The point about small-business burden, this side argues, has already been answered: the industry got the original three-year runway plus thirty additional months, and the outbreak arrived anyway. Marler adds that the four separate Cyclospora investigations with unidentified sources are themselves the evidence, since you cannot fix what you cannot trace.

Against — keep the 2028 date

Leslie G. Sarasin, President & CEO, FMI – The Food Industry Association; the Global Cold Chain Alliance

Sarasin calls FSMA 204 "the most complex regulation the food industry has ever faced," and the industry position is that a rule implemented badly produces worse data than no rule. Compliance requires every link in a chain — grower, packer, cooler, distributor, retailer — to capture matching key data elements at matching critical tracking events; a single participant still running on paper or on an incompatible system breaks the chain for everyone downstream. Many of the smallest operations, this side notes, are precisely the produce growers and regional distributors least able to fund the systems work, and forcing a premature deadline pushes some of them out of the market entirely, which concentrates supply rather than making it safer. The Global Cold Chain Alliance argues the added time is what makes real pilots possible, so that when the rule does bind, the records handed to FDA are actually usable in a traceback rather than a pile of mismatched spreadsheets.

Where it might land: the FDA is expected to codify the delay in a final rule this month, while Senators Amy Klobuchar, Jon Ossoff, and Greg Stanton have open letters to HHS on the related question of CDC FoodNet surveillance cuts. The House is out until August 31 and the Senate until August 7, so nothing legislative moves before September.

C · On My Radar

D · Trends to Watch

E · Ideas & Opportunities

H · Background / Already Covered
📚 Archive · last 7 morning reports